U.S. Personal Products Stock News

NasdaqGS:GLIB.A
NasdaqGS:GLIB.ATelecom

A Look At GCI Liberty (GLIB.A) Valuation After Recent Share Price Weakness

Recent performance and why GCI Liberty is on investors’ radar GCI Liberty (GLIB.A) has drawn fresh attention after a period of weaker share performance, with the stock down about 32% over the past month and 35% over the past 3 months. See our latest analysis for GCI Liberty. With the share price at US$25.59 and short term share price returns of 10.9% over the past week and 32.4% over the past month, recent weakness has added to a year to date share price decline of 28.6%. This suggests...
NYSE:PRM
NYSE:PRMChemicals

Assessing Perimeter Solutions (PRM) Valuation After Strong Q1 2026 Results And Rapid Share Price Gains

Perimeter Solutions (PRM) has drawn fresh attention after first quarter 2026 results showed sales of US$125.07 million and net income of US$72.94 million, along with a renewed emphasis on acquisitions and disciplined capital deployment. See our latest analysis for Perimeter Solutions. The earnings and acquisition comments have landed after a strong run in the stock, with a 30 day share price return of 19.53% and a 1 year total shareholder return of 181.13%, suggesting that momentum has been...
NasdaqGM:NRIX
NasdaqGM:NRIXBiotechs

A Look At Nurix Therapeutics (NRIX) Valuation After New NX-5948 Data And EHA Congress Selection

Nurix Therapeutics (NRIX) is back in focus after reporting new preclinical and Phase 1 data for its BTK degrader NX-5948, and after securing an oral presentation slot at the European Hematology Association Congress. See our latest analysis for Nurix Therapeutics. Despite the recent NX-5948 data and the upcoming European Hematology Association presentation, Nurix Therapeutics’ share price has eased over the past month, with a 30 day share price return of 9.45% down, even as the 1 year total...
NYSE:CC
NYSE:CCChemicals

Chemours (CC) Is Down 8.4% After Issuing 2026 Profit Guidance Amid Q1 Net Loss

The Chemours Company recently reported first quarter 2026 results, with sales of US$1,381 million and a net loss of US$29 million, while also affirming a quarterly cash dividend of US$0.0875 per share. At the same time, Chemours issued new guidance calling for sequential net sales growth in the second quarter of 2026 and full‑year 2026 net income attributable to the company between US$165 million and US$225 million, framing a clearer profitability path after a period of losses. Now we’ll...
NYSE:NHI
NYSE:NHIHealth Care REITs

The Bull Case For National Health Investors (NHI) Could Change Following Q1 2026 Beat And New Guidance

National Health Investors, Inc. reported past first-quarter 2026 results with sales of US$73.15 million, total revenue of US$115.13 million, and net income of US$40.10 million, while also declaring a second-quarter dividend of US$0.92 per common share payable on August 7, 2026. Importantly, management also issued full-year 2026 net income guidance of about US$703.00 million to US$705.20 million, giving investors a clearer view of expected profitability. Next, we’ll examine how this higher...
NasdaqGS:AVPT
NasdaqGS:AVPTSoftware

AvePoint (AVPT) Valuation In Focus After Q1 Earnings Beat And Higher Revenue Guidance

AvePoint earnings jump and higher revenue guidance put Q1 performance in focus AvePoint (AVPT) is back on investor radars after reporting first quarter revenue of US$117.24 million and net income of US$15.25 million, along with higher revenue guidance for both the second quarter and full year 2026. See our latest analysis for AvePoint. The earnings beat, higher revenue guidance and progress on the buyback have arrived against a weak share price backdrop, with AvePoint’s stock down 24.9% year...
NasdaqCM:TOI
NasdaqCM:TOIHealthcare

Undervalued Small Caps With Insider Buying For May 2026

Over the last 7 days, the United States market has remained flat, yet it has experienced a notable 24% rise over the past year with earnings expected to grow by 17% annually in the coming years. In this context, identifying small-cap stocks that are undervalued and show signs of insider buying can be a strategic approach for investors seeking opportunities that align with these market dynamics.
NasdaqGM:HVII
NasdaqGM:HVIICapital Markets

Hennessy Capital Investment VII And 2 Insider-Favored Growth Stocks To Watch

Over the last 7 days, the United States market has remained flat, yet it has experienced a notable rise of 24% over the past year, with earnings projected to grow by 17% annually in the coming years. In this context of steady market performance and promising growth expectations, identifying stocks with high insider ownership can be a key factor for investors seeking companies where management's interests are closely aligned with those of shareholders.
NasdaqGM:DIBS
NasdaqGM:DIBSMultiline Retail

3 Promising Penny Stocks With Market Caps Under $200M

Over the last 7 days, the United States market has remained flat, but it has risen 24% over the past 12 months with earnings forecasted to grow by 17% annually. For investors willing to explore beyond well-known companies, penny stocks—often representing smaller or newer entities—can present unexpected opportunities. Despite their vintage name, these stocks can still provide surprising value and potential for growth when backed by solid financial foundations.
NYSE:ACN
NYSE:ACNIT

3 Dividend Stocks To Consider For Your Portfolio

The United States market remained flat over the last week but has seen a 24% increase over the past year, with earnings forecast to grow by 17% annually. In this context, dividend stocks can be an attractive option for investors seeking steady income and potential growth in a dynamic market environment.